Abbott Recovers
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more than 2% in premarket trading.
Abbott Elementary Announced Its Renewed For Season 5
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
The U.S. Border Patrol chief’s official X account posted Tuesday that Texas "border czar" Mike Banks was the agency’s 27th ...
Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday. The company’s ...
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback